

EXPRESS MAIL NUMBER: EV055479714US

23

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kavanaugh et al.
Application No. : 09/640,041
Filed : August 15, 2000
5 For : EGFH2 GENES AND GENE PRODUCTS

Examiner : Margaret E. Jamroz
Art Unit : 1644
Docket No. : 59516-135/PP-01615.002
10 Date : February 26, 2003

Commissioner for Patents
Washington, DC 20231

15 **AFFIDAVIT OF DR. JUDITH ABRAHAM UNDER 37 C.F.R. § 1.132**

Sir:

I, Judith Abraham, Ph.D., being duly sworn, say:

1. I am an internationally recognized scientist and am presently employed at Chiron
20 Corporation, Emeryville, California (from June, 2000 to present), where I hold the position of
Director, Research. I received a Bachelors degree in Biology from the University of California,
Riverside, and a Ph.D. degree from the University of California, Berkeley, in Molecular Biology.

2. I am an author or co-author of more than 50 peer-reviewed research articles and
have been invited to give numerous presentations on my research at national and international
25 meetings. My curriculum vitae is attached.

3. In my capacity as Director of Research at Chiron Corporation, and in my prior
work, I am familiar with identifying and characterizing proteins, based on homology (both
sequence alignment and structural homology), using methods well-known to those of ordinary
skill in the art at the time of filing of the above-identified patent application. I am also familiar

with methods of protein expression and methods of assaying biological activity of proteins, particularly growth factors.

4. I understand that claims of the above-referenced patent application are rejected under 35 U.S.C. § 112, first paragraph, on the grounds that although the specification is enabling for an isolated nucleic acid molecule comprising SEQ ID NO:3, which encodes a polypeptide comprising SEQ ID NO:4, the specification allegedly does not enable nucleic acids that encode polypeptides that are at least 90% identical to the polypeptide of SEQ ID NO:4.

5. I have reviewed the patent application referenced above entitled "EGFH2 Genes and Gene Products," and I am very familiar with the subject matter of the application. At page 7, lines 3-16, the application describes a family of receptors for neuregulins, referred to as ErbB. EGFH2 is also known as NRG4 (neuregulin 4) and functions by signaling through an ErbB receptor. Thus, the biological activity of the NRG4 of the invention can be assayed by measuring the effect of NRG4 binding to its ErbB receptor.

6. The receptor for NRG4 is known in the art as ErbB4, and is discussed in the patent application at page 7, lines 8-9. Binding of NRG4 to ErbB4 can be assayed using a known cell line that lacks endogenous ErbB4 expression (myeloid 32D cells) and which have been engineered to express ErbB4 receptors, as described in Pinkas-Kramarski *et al.*, *EMBO Jour.* 15:2452-2467 (1996) and Shelly *et al.*, *J. Biol. Chem.* 273:10496-10505 (1998). Survival of these cells in the presence of NRG4 and in the absence of cytokine, such as IL-3, indicates functional binding of NRG4 (EGFH2) to the ErbB4 receptor.

7. Because this assay provides a definitive result, specifically the survival of a 32D cell line engineered to express ErbB4, one of skill in the art can use this system to assay proteins that have at least 90% sequence identity with EGFH2, as shown in SEQ ID NO:4. As a person of skill in the art, it is my opinion that it would entail only routine experimentation to express a nucleic acid encoding a polypeptide having at least 90% sequence identity with SEQ ID NO:4, and assay the polypeptide for its ability to bind ErbB4 and thereby permit the survival of 32D cells expressing ErbB4. These techniques were available in the art prior to the filing date of this


application, and are also conveniently summarized in Harari, D. *et al.*, *Oncogene* 18:2681-2689, 1999, which, on information and belief, is of record in the application.

8. Paragraphs 5-7 above describe one assay for EGFH2 biological activity. A separate assay is disclosed in the application as filed at pages 38-39. Specifically, cDNA
5 encoding EGFH2, or a polypeptide having at least 90% identity with SEQ ID NO:4, is cloned and transcribed, and the corresponding mRNA is obtained. The mRNA is injected, using routine methods, into *Xenopus* oocytes and the germinal vesicle breakdown is assayed. While antisense EGFH2 mRNA does not cause germinal vesicle breakdown, sense EGFH2 mRNA does, and the presence of germinal vesicle breakdown in oocytes injected with mRNA within the scope of the
10 claims will indicate that the mRNA encodes functional EGFH2.

9. A third method for assaying the biological activity of a polypeptide having at least 90% identity to the EGFH2 of SEQ ID NO:4 entails expressing the polypeptide in a baculovirus – insect cell expression system, purifying the polypeptide using routine protein purification methods, and then assaying the ability of the polypeptide to stimulate phosphorylation of the
15 receptor ErbB4. For this assay, the EGFH2 polypeptide is added to cells known to express ErbB4, such as the human breast cancer cell line MDA-MB-453 (Sepp-Lorenzino, L. *et al.* *Oncogene* 12:1679-1687, 1996). The ErbB4 from the cells can be readily isolated after cell lysis and membrane solubilization, by immunoprecipitation using an antibody specific for ErbB4. The precipitated protein is then fractionated by electrophoresis on a sodium dodecyl sulfate-
20 polyacrylamide gel, and transferred to a membrane utilizing the technique of Western blotting. The degree of phosphorylation of the ErbB4 receptor is measured by probing the membrane with an antibody specific for phosphotyrosine. If the phosphotyrosine content of the ErbB4 receptor is higher in cells treated with the EGFH2 polypeptide than in control cells not exposed to the polypeptide, then the EGFH2 polypeptide is judged to be functional. The patent application as
25 filed discloses ErbB4, and at the time of filing it was known that (a) antibodies to ErbB4 could be raised, and (b) ErbB4 is a tyrosine kinase and is capable of being phosphorylated, which can be detected using radiolabel or an anti-phosphotyrosine antibody, for example.

10. In conclusion, it is my opinion, as one of skill in this art, that the knowledge, techniques and reagents available at the time of filing of the above-identified patent application could be used to measure the EGFH2 biological activity of a polypeptide having at least 90% identity to SEQ ID NO:4.


5 11. I further declare that all statements made herein of my own knowledge are true and that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code.


10 
Judith Abraham

State of California)

County of Alameda) ss.:

15 On this 25th day of February, 2003, before me, a Notary Public in and for the State and County aforesaid, personally appeared Judith Abraham, to me known and known to me to be the person of that name, who signed and sealed the foregoing instrument, and she
20 acknowledged the same to be her free act and deed.


Notary Public



Commission expires 11/23/05

JUDITH A. ABRAHAM, Ph.D.

Curriculum Vitae

Work Address: Chiron Corporation
4560 Horton Street, M/S 4.455
Emeryville, CA 94608

Home Address: 4901 Country Lane
San Jose, CA 95129

Work Phone: (510) 923-2457

Work Fax: (510) 923-5550

E-mail: judy_abraham@chiron.com

EDUCATION:

1971 - 1975 University of California, Riverside, California
B.A., Biology

1975 - 1980 University of California, Berkeley, California
Ph.D., Molecular Biology (Thesis Advisor: Harrison Echols)

EMPLOYMENT HISTORY:

1980 - 1983 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Postdoctoral Fellow (Advisor: James Hicks)

1983 - 2000 Scios Inc. / Scios Nova Inc. / California Biotechnology Inc.*
1983 - 1990 *Staff Scientist*

1985 - 1989 FGF Project Leader (Research) / Manager (Development)

1989 - 1999 FGF Product Team Member (Clinical Testing Phase)

1988 - 1991 VEGF Project Leader

1990 - 2000 *Principal Scientist*

1990 - 1993 HB-EGF Project Leader

1994 - 1996 Mac-1 Project Leader

1997 - 2000 VEGF Project Leader (Research) / Manager (Development)

2000 - present Chiron Corporation

2000 - 2001 *Associate Director, Research*

2001 - present *Director, Research*

* Scios Nova was formed through a merger of California Biotechnology and Nova Pharmaceutical Corp. in 1992; the name was subsequently shortened to Scios Inc.

FELLOWSHIPS AND ACADEMIC HONORS:

| | |
|-------------|--|
| 1975 | Phi Beta Kappa, University of California, Riverside Chapter |
| 1975 | Summa Cum Laude Graduate, University of California, Riverside |
| 1975 | Outstanding Student Award, College of Natural and Agricultural Sciences, University of California, Riverside |
| 1975 - 1976 | Regents Fellowship, University of California, Berkeley |
| 1976 - 1980 | Regents Intern Fellowship, University of California, Berkeley |
| 1981 - 1983 | Damon Runyon - Walter Winchell Postdoctoral Fellowship |

MEMBERSHIPS AND SCIENTIFIC ORGANIZATION POSITIONS HELD:

American Society for Investigative Pathology

North American Vascular Biology Organization

The Wound Healing Society

Board of Directors, 1996 – 1999

Organizer, 1997 Annual Meeting

American Association for the Advancement of Science

American Heart Association

PUBLICATIONS:

1. **Abraham, J.A.**, D. Mascarenhas, R. Fischer, M. Benedik, A. Campbell, and H. Echols (1980) "DNA sequence of regulatory region for integration gene of bacteriophage lambda". *Proc. Natl. Acad. Sci. USA* **77**: 2477-2481.
2. **Abraham, J.A.**, and H. Echols (1981) "Regulation of int gene transcription by bacteriophage lambda: Location of the RNA start generated by an int constitutive mutation". *J. Mol. Biol.* **146**: 157-165.
3. Miller, H.I., **J.A. Abraham**, M. Benedik, A. Campbell, D. Court, H. Echols, R. Fischer, J.M. Galindo, G. Guarneros, T. Hernandez, D. Mascarenhas, C. Montanez, D. Schindler, U. Schmeissner, and L. Sosa (1981) "Regulation of the integration - excision reaction by bacteriophage lambda". *Cold Spring Harbor Symp. Quant. Biol.* **45**: 439-445.
4. Strathern, J.R., A.J.S. Klar, J.B. Hicks, **J.A. Abraham**, J.M. Ivy, K.A. Nasmyth, and C. McGill (1982) "Homothallic switching of yeast mating-type cassettes is initiated by a double-stranded cut in the MAT locus". *Cell* **31**: 183-192.
5. **Abraham, J.A.**, J. Feldman, K.A. Nasmyth, J.N. Strathern, A.J.S. Klar, J.R. Broach, and J.B. Hicks (1983) "Sites required for position-effect regulation of mating-type information in yeast". *Cold Spring Harbor Symp. Quant. Biol.* **47**: 989-998.
6. Broach, J.R., Y.-Y. Li, J. Feldman, M. Jayaram, **J. Abraham**, K.A. Nasmyth, and J.B. Hicks (1983) "Localization and sequence analysis of yeast origins of DNA replication". *Cold Spring Harbor Symp. Quant. Biol.* **47**: 1165-1173.
7. **Abraham, J.A.**, K.A. Nasmyth, J.N. Strathern, A.J.S. Klar, and J.B. Hicks (1984) "Regulation of mating-type information in yeast: Negative control requiring sequences both 5' and 3' to the regulated region". *J. Mol. Biol.* **176**: 307-331.
8. Klar, A.J.S., J.N. Strathern, and **J.A. Abraham** (1984) "Involvement of double-strand chromosomal breaks for mating-type switching in *Saccharomyces cerevisiae*". *Cold Spring Harbor Symp. Quant. Biol.* **49**: 77-88.
9. Brand, A.H., L. Breeden, **J. Abraham**, R. Sternglanz, and K. Nasmyth (1985) "Characterization of a "silencer" in yeast: A DNA sequence with properties opposite to those of a transcriptional enhancer". *Cell* **41**: 41-48.
10. Winoto, A., S. Chung, **J. Abraham**, and H. Echols (1986) "Directional control of site-specific recombination by bacteriophage lambda: Evidence that a binding site for Int protein far from the crossover point is required for integrative but not excisive recombination". *J. Mol. Biol.* **192**: 677-680.
11. Vlasuk, G.P., G.H. Bencen, R.M. Scarborough, P.-K. Tsai, J.L. Whang, T. Maack, M.J.F. Camargo, S.W. Kirsher, and **J.A. Abraham** (1986) "Expression and secretion of biologically active human atrial natriuretic peptide in *Saccharomyces cerevisiae*". *J. Biol. Chem.* **261**: 4789-4796.

12. **Abraham, J.A.**, A. Mergia, J.L. Whang, A. Tumolo, J. Friedman, K.A. Hjerrild, D. Gospodarowicz, and J.C. Fiddes (1986) "Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor". *Science* **233**: 545-548.
13. Mergia, A., R. Eddy, **J.A. Abraham**, J.C. Fiddes, and T.B. Shows (1986) "The genes for basic and acidic fibroblast growth factors are on different chromosomes". *Biochem. Biophys. Res. Commun.* **138**: 644-651.
14. **Abraham, J.A.**, J.L. Whang, A. Tumolo, A. Mergia, J. Friedman, D. Gospodarowicz, and J.C. Fiddes (1986) "Human basic fibroblast growth factor: Nucleotide sequence and genomic organization". *EMBO Journal* **5**: 2523-2528.
15. **Abraham, J.A.**, J.L. Whang, A. Tumolo, A. Mergia, and J.C. Fiddes (1986) "Human basic fibroblast growth factor: Nucleotide sequence, genomic organization, and expression in mammalian cells". *Cold Spring Harbor Symp. Quant. Biol.* **51**: 657-668.
16. Schweigerer, L., G. Neufeld, J. Friedman, **J.A. Abraham**, J.C. Fiddes, and D. Gospodarowicz (1987) "Capillary endothelial cells express basic fibroblast growth factor, a mitogen that stimulates their own growth". *Nature* **325**: 257-259.
17. Schweigerer, L., G. Neufeld, J. Friedman, **J.A. Abraham**, J.C. Fiddes, and D. Gospodarowicz (1987) "Basic fibroblast growth factor: Production and growth stimulation in cultured adrenal cortex cells". *Endocrinology* **120**: 796-800.
18. Schweigerer, L., G. Neufeld, A. Mergia, **J.A. Abraham**, J.C. Fiddes, and D. Gospodarowicz (1987) "Basic fibroblast growth factor in human rhabdomyosarcoma cells: Implications for the proliferation and neovascularization of myoblast-derived tumors". *Proc. Natl. Acad. Sci. USA* **84**: 842-846.
19. Fiddes, J.C., J.L. Whang, A. Mergia, A. Tumolo, and **J.A. Abraham** (1987) "Genes for the angiogenic growth factors, basic and acidic fibroblast growth factor". In: *Current Communications in Molecular Biology. Angiogenesis: Mechanisms and Pathobiology* (D.B. Rifkin and M. Klagsbrun, eds.). Cold Spring Harbor, New York, pp. 24-31.
20. Blam, S.B., R. Mitchell, E. Tischer, J.S. Rubin, M. Silva, S. Silver, J.C. Fiddes, **J.A. Abraham**, and S.A. Aaronson (1988) "Addition of growth hormone secretion signal to basic fibroblast growth factor results in cell transformation and secretion of aberrant forms of the protein". *Oncogene* **3**: 129-136.
21. Kimelman, D., **J.A. Abraham**, T. Haaparanta, T.M. Palisi, and M.W. Kirschner (1988) "The presence of fibroblast growth factor in the frog egg: Its role as a natural mesoderm inducer". *Science* **242**: 1053-1056.
22. Mergia, A., E. Tischer, D. Graves, A. Tumolo, J. Miller, D. Gospodarowicz, **J.A. Abraham**, G.D. Shipley, and J.C. Fiddes (1989) "Structural analysis of the gene for human acidic fibroblast growth factor". *Biochem. Biophys. Res. Commun.* **164**: 1121-1129.

23. Gospodarowicz, D., **J.A. Abraham**, and J. Schilling (1989) "Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells". *Proc. Natl. Acad. Sci. USA* **86**: 7311-7315.
24. Tischer, E., D. Gospodarowicz, R. Mitchell, M. Silva, J. Schilling, K. Lau, T. Crisp, J.C. Fiddes, and **J.A. Abraham** (1989) "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family". *Biochem. Biophys. Res. Commun.* **165**: 1198-1206.
25. Thompson, S.A., A.A. Protter, L. Bitting, J.C. Fiddes, and **J.A. Abraham** (1990) "Cloning, recombinant expression, and characterization of basic fibroblast growth factor". *Methods Enzymol.* **198**: 96-116.
26. Hebda, P.A., C.K. Klingbeil, **J.A. Abraham**, and J.C. Fiddes (1990) "Basic fibroblast growth factor stimulation of epidermal wound healing in pigs". *J. Invest. Dermatol.* **95**: 626-631.
27. Fiddes, J.C., P.A. Hebda, P. Hayward, M.C. Robson, **J.A. Abraham**, and C.K. Klingbeil (1991) "Preclinical wound-healing studies with recombinant human basic fibroblast growth factor". In: *Annals of the New York Academy of Sciences, Volume 638: The Fibroblast Growth Factor Family*, pp. 316-328.
28. Higashiyama, S., **J.A. Abraham**, J. Miller, J.C. Fiddes, and M. Klagsbrun (1991) "A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF". *Science* **251**: 936-939.
29. Tischer, E., R. Mitchell, T. Hartman, M. Silva, D. Gospodarowicz, J.C. Fiddes, and **J.A. Abraham** (1991) "The human gene for vascular endothelial growth factor: Multiple protein forms are encoded through alternative exon splicing". *J. Biol. Chem.* **266**: 11947-11954.
30. Higashiyama, S., K. Lau, G.E. Besner, **J.A. Abraham**, and M. Klagsbrun (1992) "Structure of heparin-binding EGF-like growth factor: Multiple forms, primary structure, and glycosylation of the mature protein". *J. Biol. Chem.* **267**: 6205-6212.
31. **Abraham, J.A.**, D. Damm, A. Bajardi, J. Miller, M. Klagsbrun, and R.A.B. Ezekowitz (1993) "Heparin-binding EGF-like growth factor: Characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues". *Biochem. Biophys. Res. Commun.* **190**: 125-133.
32. Higashiyama, S., **J.A. Abraham**, and M. Klagsbrun (1993) "Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: Dependence on interactions with cell surface heparan sulfate". *J. Cell Biol.* **122**: 933-940.
33. Marikovsky, M., K. Breuing, P.Y. Liu, E. Eriksson, S. Higashiyama, P. Farber, **J. Abraham**, and M. Klagsbrun (1993) "Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury". *Proc. Natl. Acad. Sci. USA* **90**: 3889-3893.

34. Powell, P.P., M. Klagsbrun, **J.A. Abraham**, and R.C. Jones (1993) "Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension." *Am. J. Pathol.* **193**: 1-10.
35. Dluz, S.M, S. Higashiyama, D. Damm, **J.A. Abraham**, and M. Klagsbrun (1993) "Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells: Induction of mRNA levels and secretion of active mitogen". *J. Biol. Chem.* **268**: 18330-18334.
36. Nakano, T., E.W. Raines, **J.A. Abraham**, F.G. Wenzel IV, S. Higashiyama, M. Klagsbrun, and R. Ross (1993) "Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding EGF-like growth factor in human aortic smooth muscle cells". *J. Biol. Chem.* **268**: 22941-22947.
37. Thompson, S.A., S. Higashiyama, K. Wood, N.S. Pollitt, D. Damm, G. McEnroe, B. Garrick, N. Ashton, K. Lau, N. Hancock, M. Klagsbrun, and **J.A. Abraham** (1994) "Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin". *J. Biol. Chem.* **269**: 2541-2549.
38. Ito, N., S. Kawata, S. Tamura, S. Kiso, H. Tsushima, D. Damm, **J.A. Abraham**, S. Higashiyama, N. Taniguchi, and Y. Matsuzawa (1994) "Heparin-binding EGF-like growth factor is a potent mitogen for rat hepatocytes". *Biochem. Biophys. Res. Commun.* **198**: 25-31.
39. Nakano, T., E.W. Raines, **J.A. Abraham**, M. Klagsbrun, and R. Ross (1994) "Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes". *Proc. Natl. Acad. Sci. USA* **91**: 1069-1073.
40. Avraham, H., N. Banu, D.T. Scadden, **J. Abraham**, and J.E. Groopman (1994) "Modulation of megakaryocytopoiesis by human basic fibroblast growth factor". *Blood* **83**: 2126-2132.
41. Das, S.K., X.-N. Wang, B.C. Paria, D. Damm, **J.A. Abraham**, M. Klagsbrun, G.K. Andrews, and S.K. Dey (1994) "Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: A possible ligand for interaction with blastocyst EGF receptor in implantation". *Development* **120**: 1071-1083.
42. Wang, X.-N., S.K. Das, D. Damm, M. Klagsbrun, **J.A. Abraham**, and S.K. Dey (1994) "Differential regulation of heparin-binding EGF-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen". *Endocrinology* **135**: 1264-1271.
43. Raab, G., S. Higashiyama, S. Hetelekidis, **J.A. Abraham**, D. Damm, M. Ono, and M. Klagsbrun (1994) "Biosynthesis and processing by phorbol ester of the cell surface-associated precursor form of heparin-binding EGF-like growth factor". *Biochem. Biophys. Res. Commun.* **204**: 592-597.

44. Ono, M., G. Raab, K. Lau, **J.A. Abraham**, and M. Klagsbrun (1994) "Purification and characterization of transmembrane forms of heparin-binding EGF-like growth factor". *Proc. Natl. Acad. Sci. USA* **269**: 31315-31321.
45. Cook, P.W., D. Damm, B.L. Garrick, K.M. Wood, C.E. Karkaria, S. Higashiyama, M. Klagsbrun, and **J.A. Abraham** (1995) "Carboxyl-terminal truncation of leucine₇₆ converts heparin-binding EGF-like growth factor from a heparin-enhancible to a heparin-suppressible growth factor". *J. Cell. Physiol.* **163**: 407-417.
46. Berardi, A.C., A. Wang, **J. Abraham**, and D.T. Scadden (1995) "Basic fibroblast growth factor mediates its effects on committed myeloid progenitors by direct action and has no effect on hematopoietic stem cells". *Blood* **86**: 2123-2129.
47. Faber-Elman, A., A. Solomon, **J.A. Abraham**, M. Marikovsky, and M. Schwartz (1996) "Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation". *J. Clin. Invest.* **97**: 162-171.
48. McCarthy, S.A., M.L. Samuels, C.A. Pritchard, **J.A. Abraham**, and M. McMahon (1995) "Rapid induction of heparin-binding epidermal growth factor / diphtheria toxin receptor expression by Raf and Ras oncogenes". *Genes & Development* **9**: 1953-1964.
49. **Abraham, J.A.**, and M. Klagsbrun (1995) "Modulation of wound repair by members of the fibroblast growth factor family". In: *The Molecular and Cellular Biology of Wound Repair* (Second Edition), (Richard A. F. Clark, editor), pp. 195-248, Plenum Publishing Co., New York.
50. Leslie, C.C., K. McCormick-Shannon, J. M. Shannon, B. Garrick, D. Damm, **J.A. Abraham**, and R.J. Mason (1997) "Heparin-binding EGF-like growth factor is a mitogen for rat alveolar type II cells". *Am. J. Resp. Cell Mol. Biol.* **16**: 379 - 387.
51. Sakai, M., M. Zhang, T. Homma, B. Garrick, **J.A. Abraham**, J.A. McKanna, and R.C. Harris (1997) "Production of heparin-binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. Isolation and localization of bioactive molecules". *J. Clin. Invest.* **99**: 2128 - 2138.
52. Abramovitch, R., M. Neeman, R. Reich, I Stein, E. Keshet, **J. Abraham**, A. Solomon, and M. Marikovsky (1998) "Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor". *FEBS Lett.* **425**: 441 - 447.
53. Feng, Y., D. Chung, L. Garrard, G. McEnroe, D. Lim, J. Scardina, K. McFadden, A. Guzzetta, A. Lam, **J. Abraham**, D. Liu, and G. Endemann (1998) "Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1". *J. Biol. Chem.* **273**: 5625-5630.
54. Feng, L., G.E. Garcia, Y. Yang, Y. Xia, F.B. Gabbai, O.W. Peterson, **J.A. Abraham**, R.C. Blantz, and C.B. Wilson (2000) "Heparin-binding EGF-like growth factor contributes to reduced glomerular filtration rate during glomerulonephritis in rats". *J. Clin. Invest.* **105**: 341-350.

55. Kalmes, A., B.R. Vesti, G. Daum, **J.A. Abraham**, and A.W. Clowes (2000) "Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor". *Circ. Res.* **87**: 92-98.
56. Henson, M., D. Damm, A. Lam, L.J. Garrard, T. White, **J.A. Abraham**, G.F. Schreiner, L.W. Stanton, and A.H. Joly (2000) "Insulin-like growth factor-binding protein-3 induces fetalization in neonatal rat cardiomyocytes". *DNA and Cell Biol.* **19**: 757-763.
57. Chen, M.M., A. Lam, **J.A. Abraham**, G.F. Schreiner, and A.H. Joly (2000) "CTGF expression is induced by TGF- β in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis". *J. Mol. Cell. Cardiol.* **32**:1805-1819.
58. Yang, H.T., Z. Yan, **J.A. Abraham**, and R.L. Terjung (2001) "VEGF₁₂₁- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production". *Am. J. Physiol. Heart Circ. Physiol.* **280**: H1097-H1104.
59. Suga, S., Y.-G. Kim, A. Joly, E. Puchacz, D.-H. Kang, J.A. Jefferson, **J.A. Abraham**, J. Hughes, R.J. Johnson, and G.F. Schreiner (2001) "Vascular endothelial growth factor (VEGF₁₂₁) protects rats from renal infarction in thrombotic microangiopathy". *Kidney International* **60**: 1297-1308.
60. Villanueva, F.S., **J.A. Abraham**, G.F. Schreiner, M. Csikari, D. Fischer, J.D. Mills, U. Schellenberger, B.J. Koci, and J.S. Lee (2002) "Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121". *Circulation* **105**: 759-765.